Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Non-Small Cell Lung Cancer
Several warning signs, or the trial stopped. The score counts warning signs; it is not a prediction.
Why this score
- +85
The trial was stopped early, so it goes straight to red
Stopped trials go straight to red
Score over time
- Stage
- Phase 3
- Patients
- 95 (final count)
- Started
- Jun 15, 2022
- Main results expected
- Sep 3, 2026
- Fully finished
- Oct 5, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression free survival (PFS)
Measured over: Approximately up to 24 months
Changes Tremor has spotted
The trial was stopped early.
Novartis has stopped a late-stage study of a lung cancer drug early, after it had been running and planned for 95 patients. The company hasn't said why it stopped. Investors watch a change like this because an early stop in a late-stage trial can sometimes signal that the drug is not working as hoped, or that it may be causing problems, and that could affect the company's future sales. The same kind of stop can also happen for ordinary reasons, such as slow patient enrollment, shifts in company priorities, or results that are not clear enough to justify continuing, so this change alone doesn't prove the drug has failed.
AI-written from the facts above
Spotted
Moved the final finish date slightly later: Oct 3, 2026 → Oct 5, 2026.
Spotted
Reworded the trial's main goal or its timing.
Spotted
Show details (technical version)
Score inputs
- trial_stopped: base 85, now 85, since 2026-11-09, no fading
Raw record changes
- 2026-11-06 15:29 UTC · trial_stopped · overall_status
old: "ACTIVE_NOT_RECRUITING"
new: "TERMINATED" - 2026-11-06 15:29 UTC · date_small_change · completion_date
old: "2026-10-03"
new: "2026-10-05"
details: {"months":0.1} - 2026-11-06 15:29 UTC · primary_outcome_reworded · primary_outcomes
old: [{"measure":"Progression free survival (PFS)","timeFrame":"Approximately up to 24 months","description":"PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause. PFS is based on central assessment and using RECIST 1.1 criteria."}]
new: [{"measure":"Progression free survival (PFS)","timeFrame":"Approximately up to 24 months","description":"PFS is the time from date of randomization to the date of event defined as the first documented disease progression based on local Investigator assessment per RECIST 1.1 criteria or death due to any cause."}]
Trial ID NCT05132075 · record last updated 2026-11-06 · checked 2026-11-09 06:30 UTC